Sohier Elneil

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6724980/publications.pdf

Version: 2024-02-01

236612 182168 2,694 77 25 51 h-index citations g-index papers 83 83 83 2069 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	EAU Guidelines on Chronic Pelvic Pain. European Urology, 2010, 57, 35-48.	0.9	381
2	Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report. European Urology, 2009, 55, 100-120.	0.9	269
3	A standard for terminology in chronic pelvic pain syndromes: A report from the chronic pelvic pain working group of the international continence society. Neurourology and Urodynamics, 2017, 36, 984-1008.	0.8	142
4	Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Annals of Neurology, 2007, 62, 452-457.	2.8	134
5	Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity. European Urology, 2008, 53, 1245-1253.	0.9	133
6	Complications following vaginal mesh procedures for stress urinary incontinence: an 8 year study of 92,246 women. Scientific Reports, 2017, 7, 12015.	1.6	115
7	Distribution of P2X ₁ and P2X ₃ Receptors in the Rat and Human Urinary Bladder. Pharmacology, 2001, 63, 120-128.	0.9	97
8	Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU International, 2007, 101, 071027214644004-???.	1.3	84
9	The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 657-665.	0.9	80
10	Long-Term Effect on Quality of Life of Repeat Detrusor Injections of Botulinum Neurotoxin-A for Detrusor Overactivity in Patients With Multiple Sclerosis. Journal of Urology, 2011, 185, 1344-1349.	0.2	77
11	Urinary retention in women: its causes and management. BJU International, 2006, 97, 281-287.	1.3	74
12	Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment. European Urology, 2009, 55, 1440-1449.	0.9	74
13	Cost-Consequence Analysis Evaluating the Use of Botulinum Neurotoxin-A in Patients with Detrusor Overactivity Based on Clinical Outcomes Observed at a Single UK Centre. European Urology, 2006, 49, 519-527.	0.9	70
14	Comparison of connexin expression patterns in the developing mouse heart and human foetal heart. Molecular and Cellular Biochemistry, 2003, 242, 121-127.	1.4	69
15	Abdominal sacrocolpopexy for vault prolapse without burial of mesh: a case series. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 486-489.	1.1	63
16	What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A Injection. Journal of Urology, 2009, 181, 1773-1778.	0.2	62
17	Immunohistochemical Expression of Muscarinic Receptors in the Urothelium and Suburothelium of Neurogenic and Idiopathic Overactive Human Bladders, and Changes With Botulinum Neurotoxin Administration. Journal of Urology, 2010, 184, 2578-2585.	0.2	59
18	Early Effect on the Overactive Bladder Symptoms following Botulinum Neurotoxin Type A Injections for Detrusor Overactivity. European Urology, 2008, 54, 181-187.	0.9	52

#	Article	IF	Citations
19	Clean Intermittent Self-Catheterization After Botulinum Neurotoxin Type A Injections. Obstetrics and Gynecology, 2009, 113, 1046-1051.	1.2	49
20	Complex pelvic floor failure and associated problems. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 555-573.	1.0	37
21	Urinary retention in women and sacral neuromodulation. International Urogynecology Journal, 2010, 21, 475-483.	0.7	36
22	The Possible Role of Opiates in Women with Chronic Urinary Retention: Observations from a Prospective Clinical Study. Journal of Urology, 2012, 188, 480-484.	0.2	34
23	A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints. Neurourology and Urodynamics, 2018, 37, 1060-1067.	0.8	34
24	Development of a Unifying Target and Consensus Indicators for Global Surgical Systems Strengthening: Proposed by the Global Alliance for Surgery, Obstetric, Trauma, and Anaesthesia Care (The G4 Alliance). World Journal of Surgery, 2017, 41, 2426-2434.	0.8	32
25	A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12â€month results from the RELAXâ€OAB study. Neurourology and Urodynamics, 2019, 38, 689-695.	0.8	27
26	Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourology and Urodynamics, 2018, 37, S9-S16.	0.8	26
27	Benefits and Harms of Electrical Neuromodulation for Chronic Pelvic Pain: A Systematic Review. European Urology Focus, 2020, 6, 559-571.	1.6	24
28	Staging and Preparation of Human Fetal Striatal Tissue for Neural Transplantation in Huntington's Disease. Cell Transplantation, 2003, 12, 679-686.	1.2	23
29	Comparison of the impact on healthâ€related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU International, 2011, 107, 1786-1792.	1.3	23
30	Comparison of Connexin 43, 40 and 45 Expression Patterns in the Developing Human and Mouse Hearts. Cell Communication and Adhesion, 2001, 8, 339-343.	1.0	22
31	Pregnancy in women with Fowler's syndrome treated with sacral neuromodulation. International Urogynecology Journal, 2013, 24, 1201-1204.	0.7	22
32	Sacral Neuromodulation Outcomes in Male Patients with Chronic Urinary Retention. Neuromodulation, 2015, 18, 329-334.	0.4	20
33	Female sexual dysfunction in female genital mutilation. Tropical Doctor, 2016, 46, 2-11.	0.2	18
34	An International Continence Society (ICS) report on the terminology for female pelvic floor fistulas. Neurourology and Urodynamics, 2020, 39, 2040-2071.	0.8	18
35	Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourology and Urodynamics, 2018, 37, S17-S22.	0.8	17
36	A systematic review and meta-analysis of the Endometriosis and Mental-Health Sequelae; The ELEMI Project. Women's Health, 2021, 17, 174550652110197.	0.7	17

#	Article	IF	CITATIONS
37	Transplanted Human Neural Precursor Cells Migrate Widely but Show no Lesion-Specific Tropism in the 6-Hydroxydopamine Rat Model of Parkinson's Disease. Cell Transplantation, 2006, 15, 579-593.	1.2	15
38	Cadherin-11 Up-Regulation in Overactive Bladder Suburothelial Myofibroblasts. Journal of Urology, 2009, 182, 190-195.	0.2	15
39	Optimizing the Duration of Assessment of Stage-1 Sacral Neuromodulation in Nonobstructive Chronic Urinary Retention. Neuromodulation, 2014, 17, 66-71.	0.4	15
40	Twoâ€year safety and efficacy outcomes for the treatment of overactive bladder using a longâ€lived rechargeable sacral neuromodulation system. Neurourology and Urodynamics, 2020, 39, 1108-1114.	0.8	12
41	Obstetric fistula―a new way forward. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 30-32.	1.1	11
42	Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks. European Urology, 2010, 57, 891-896.	0.9	11
43	In the Human Urothelium and Suburothelium, Intradetrusor Botulinum Neurotoxin Type A Does Not Induce Apoptosis: Preliminary Results. European Urology, 2010, 57, 879-883.	0.9	11
44	The Benefits and Harms of Botulinum Toxin-A in the Treatment of Chronic Pelvic Pain Syndromes: A Systematic Review by the European Association of Urology Chronic Pelvic Pain Panel. European Urology Focus, 2022, 8, 320-338.	1.6	11
45	3-Year Followup of a New Implantable Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome. Journal of Urology, 2020, 204, 545-550.	0.2	11
46	Gynaecological pathology in women with Fowler's syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 194, 54-57.	0.5	10
47	Management of chronic primary pelvic pain syndromes. BJU International, 2022, 129, 572-581.	1.3	9
48	Activation of epithelial Na+ channel activity in the rabbit urinary bladder by cAMP. European Journal of Pharmacology, 2000, 404, 273-280.	1.7	6
49	Global efforts for effective training in fistula surgery. International Journal of Gynecology and Obstetrics, 2015, 131, S64-6.	1.0	5
50	Repairing the female pelvic floor: when good enough is not good enough. Nature Reviews Urology, 2018, 15, 197-198.	1.9	5
51	Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab. Journal of Translational Autoimmunity, 2021, 4, 100097.	2.0	5
52	Demand and capacity to integrate pelvic organ prolapse and genital fistula services in low-resource settings. International Urogynecology Journal, 2018, 29, 1509-1515.	0.7	4
53	SINGLE CENTRE RANDOMISED PILOT STUDY OF TWO REGIMENS (30 MINS DAILY OR 30 MINS WEEKLY FOR 12) TO SCLEROSIS-RELATED OVERACTIVE BLADDER SYMPTOMS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4,20-e4.	j ETQq1 1 0.9	0.784314
54	Patientâ€tailored healthcare and tibial nerve neuromodulation in the treatment of patients with overactive bladder symptoms. Neurourology and Urodynamics, 2022, 41, 679-684.	0.8	3

#	Article	IF	CITATIONS
55	Evaluation and management of neurogenic sexual dysfunction., 0,, 153-166.		2
56	Occupational risk prevention, education and support in black, Asian and ethnic minority health worker in the COVID-19 pandemic. Journal of Patient Safety and Risk Management, 2020, 25, 205-209.	0.4	2
57	Long-term Patient Satisfaction and Function After Sacrocolpopexy for Vault Prolapse Repair. Journal of Pelvic Medicine & Surgery, 2007, 13, 133-139.	0.1	1
58	Neurogenic bladder dysfunction: surgical interventional approaches., 0,, 112-126.		1
59	Recurrent Urinary Tract Infections Associated with Gynecological Disorders. Current Bladder Dysfunction Reports, 2012, 7, 131-140.	0.2	1
60	Neural stimulators: A guide to imaging and postoperative appearances. Clinical Radiology, 2014, 69, 993-1003.	0.5	1
61	2721 Specific features of gap junction composition correlate with the slow and fast conduction pathways to the human atioventricular node. European Heart Journal, 2003, 24, 505.	1.0	1
62	1184: 10-Year Experience of Sacral Neuromodulation in Urinary Retention - Results from UK Tertiary Referral Centre. Journal of Urology, 2007, 177, 390-391.	0.2	1
63	Connexin expression in the developing mouse heart and human foetal heart. Journal of Molecular and Cellular Cardiology, 2001, 33, A23.	0.9	O
64	MP-04.05. Urology, 2006, 68, 70.	0.5	0
65	SUBUROTHELIAL MUSCARINIC RECEPTORS M1, M2, M3 IN PATIENTS WITH DETRUSOR OVERACTIVITY (DO) AND THE EFFECT OF BOTULINUM TOXIN TYPE A (BONT/A). European Urology Supplements, 2008, 7, 184.	0.1	O
66	PERIODIC INTRA-DETRUSOR INJECTIONS OF BOTULINUM NEUROTOXIN TYPE-A IN PATIENTS WITH INTRACTABLE DETRUSOR OVERACTIVITY. Journal of Urology, 2008, 179, 567-567.	0.2	0
67	Uro-Neurology. , 0, , 893-912.		O
68	Obstetric Fistula—A New Way Forward. Obstetric Anesthesia Digest, 2010, 30, 248-249.	0.0	0
69	Obstetric fistulae in the developing world. British Journal of Midwifery, 2010, 18, 250-252.	0.1	O
70	PAW26 Are the beneficial effects of Botulinum toxin for refractory detrusor overactivity in multiple sclerosis sustained with repeat injections?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e30-e31.	0.9	0
71	512 SACRAL NEUROMODULATION FOR NEUROGENIC LOWER URINARY TRACT DYSFUNCTION: A VALUABLE TREATMENT OPTION?. European Urology Supplements, 2010, 9, 178.	0.1	O
72	PERCUTANEOUS TIBIAL NERVE STIMULATION FOR OVERACTIVE BLADDER. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.138-e4.	0.9	0

SOHIER ELNEIL

#	Article	IF	CITATIONS
73	FOWLER'S SYNDROME OF URINARY RETENTION: A RETROSPECTIVE STUDY OF CO-MORBIDITY. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e3.62-e3.	0.9	0
74	FOWLER'S SYNDROME OF URINARY RETENTION: A RETROSPECTIVE STUDY OF CO-MORBIDITY. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.74-e4.	0.9	0
75	The surgeon fixing a scandal. New Scientist, 2018, 239, 36-37.	0.0	O
76	The ultrastructural study of suburothelial unmyelinated nerve profile in women with urinary stress incontinence. (LB80). FASEB Journal, 2014, 28, LB80.	0.2	0
77	Pharmacological Treatment of Chronic Pelvic Pain. , 2021, , 945-949.		0